Diligence memo · auto-generated · as of July 2, 2026
SignalRX Pharmaceuticals, Inc
SignalRX Pharmaceuticals, Inc looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
SignalRX Pharmaceuticals, Inc operates in Pharmaceuticals, based in CUMMING.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
SignalRX Pharmaceuticals, Inc has raised $250K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $250K on 2022-09-16.
Most recent recorded round closed around 2022-09-16.
Valuation (modeled)modeled
Provath models SignalRX Pharmaceuticals, Inc at approximately $3.2M (range $140K–$19M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.27× the median modeled value of Pre-Seed Pharmaceuticals companies in 2022–2024 (38 peers) — value vs value, same stage and era. Within the normal band (127% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 3.8 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 6% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 6% of those peers.
Closest niche peers: Eleison Pharmaceuticals Inc, Telomir Pharmaceuticals, Inc., Drusolv Therapeutics, Inc., TF Tech Ventures, Inc., Thyron Pharmaceuticals, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.